1Cannistra SA. Cancer of the ovary. N Eng J Med 2004, 351: 2519-2529.
2Ozols RF. Treatment goals in ovarian cancer, lnt J Gynecol Cancer 2005, 15:3- 11.
3Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M and McMeekin DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005, 96: 10-18.
4Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5: 275-284.
5Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW and Hoey T, et al. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58: 267-284.
6Sanchez-Garcia I, Vicente-Duefias C and Cobaleda C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays 2007, 29:1269 1280.
7Bapat SA, Mall AM, Koppikar CB and Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65: 3025--3029.
8Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R and Dombkowski D, et al. Ovarian cancer side population defines cells with stem celMike characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006, 103:11154-11159.
9Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM and Yan PS, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311- 4320.
10Teramura T, Fukuda K, Kurashimo S, Hosoi Y, Miki Y, Asada S and Hamanishi C. Isolation and characterization of side population stem cells in articular synovial tissue. BMC Musculoskelet Disord 2008, 9:86- 98.
